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Clinical review
Squamous cell carcinomas of the head and neck
R J Sanderson, J A D Ironside
Public awareness of this common form of cancer needs to be increased because despite important
advances in treatment, prognosis still largely depends on the stage of presentation
More than 90% of tumours in the head and neck are
squamous carcinomas. Cancer of the head and neck,
which can arise in several places, is often preventable,
and if diagnosed early is usually curable. Unfortunately,
patients often present with advanced disease that is
incurable or requires aggressive treatment, which leaves
them functionally disabled. We have reviewed current
practice and potential future advances in the referral,
diagnosis, and management of head and neck cancer.
Methods
We gathered information from several sources, includ›
ing personal experience of treating head and neck
cancer in a multidisciplinary tertiary referral centre
and the Medline and Cochrane databases.
Incidence
Squamous cell cancer of the head and neck is one of
the most common cancers worldwide, with incidences
of more than 30 per 100 000 population in India (oral
cancer) and in France and Hong Kong (nasopharyn›
geal cancer). It constitutes about 4% of all cancers in
the United States and 5% in the United Kingdom. A
total of 2940 new cases of lip, mouth, and pharyngeal
cancer in men were reported in the United Kingdom
in 1996: an incidence of 10.2 per 100 000 population.1
People in their 40s and 50s are most susceptible. The
3:1 ratio of prevalence in men to women is decreasing:
in the past 10 years the incidence in Scotland has risen
by 19.4% in men and 28.7% in women.2 In the United
Kingdom incidence and mortality are greater in
deprived populations, most notable in carcinoma of
the tongue.2
Causes
Smoking tobacco, drinking alcohol, and having a poor
diet are important risk factors in the West, and chewing
betel or areca nuts, smoking bidis, and taking snuff are
important in the Indian subcontinent. Epstein›Barr
virus has been implicated in nasopharyngeal carci›
noma, and hypopharyngeal carcinoma in elderly
women has been associated with a pre›existing post›
cricoid web. A total of 70% of tumours show loss of
heterozygosity near genome 9p21, which may indicate
loss of a gene that suppresses tumours.3
Presentation
Most head and neck cancers present with symptoms
from the primary site—for example, hoarseness, diffi›
culty in swallowing, or pain in the ear. Enlargement of
a cervical lymph node as the first presenting feature is
not uncommon, particularly with certain “silent” sites—
the tongue base, supraglottis, and nasopharynx. Sys›
temic metastases are uncommon at presentation (10%),4
however, synchronous or metachronous tumours of the
upper aerodigestive tract occur in 10›15% of patients.5
Guidelines have been written for general medical and
dental practitioners for referring patients with suspected
malignancies of the head and neck (box 1), and most
head and neck units have an open access clinic to see
these patients urgently.6 Removing the node before
referral to a specialist centre without first identifying the
primary tumour is associated with increased morbidity
and poorer long term outcome.7
Screening and early diagnosis
Primary prevention—stopping smoking and drinking
less alcohol—is the most effective way to reduce
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mortality. Early detection should be a priority, given the
excellent prognosis of early stage disease compared with
the poor results in advanced stages. In Indian screening
programmes, community health workers have been
trained in primary prevention and early detection of
oral cancer and premalignant lesions, but no evidence
suggests that this reduces mortality. Screening is most
cost effective when targeted at high risk groups—for
example, heavy drinkers and smokers.
In the United Kingdom there is relatively little pub›
lic awareness of head and neck cancer, although
individual centres have taken local initiatives. Dentists
largely carry the responsibility for examining the oral
mucosa in the self selected population that attends for
treatment.
Chemoprevention
Retinoids, vitamin A, N›acetyl›cysteine, and other agents
may prevent recurrence in patients at risk or prevent
malignant transformation in precancerous conditions
such as leukoplakia, but no evidence suggests that these
treatments are effective in routine clinical practice.8
Investigation
Diagnosis is confirmed by biopsy of the primary site
and fine needle aspiration of any enlarged lymph
nodes. A full panendoscopy allows full assessment of
the extent of the tumour and exclusion of tumours at
other sites within the head and neck. Most centres in
the United Kingdom recommend computed tomo›
graphy of the chest to pick up synchronous early lung
tumours or metastases.
Imaging of the head and neck
Imaging is crucial in assessing the site, extent, and rela›
tionships of a histologically proved primary tumour
and to detect the presence of enlarged lymph nodes.
After imaging, the staging of the tumour or node is
upgraded in at least 30% of cases. Computed tomogra›
phy is the mainstay of assigning advanced head and
neck malignancy a stage because it is generally
available. Magnetic resonance imaging is the preferred
tool for investigating the primary tumour in all head
and neck sites, particularly for assessing cartilage, bone,
perineural, and perivascular invasion. A combination
of neck ultrasonography and fine needle aspiration
improves the specificity of staging of cervical lymph
nodes. Although not widely available, positron
emission tomography is useful for detecting recurrent
disease in the head and neck.
Staging
Staging is done according to the International Union
Against Cancer’s (UICC) classification system for oral
cancer.9
x Stage I—T1 N0 M0
x Stage II—T2 N0 M0
x Stage III—T3 N0, T1›3 N1, and M0
x Stage IV—T4 any N, T1›3 N2›3, any T any N M1
(T=tumour; N=node; M=metastasis.)
Multidisciplinary team
Head and neck tumours can occur at a large number of
subsites, often invading more than one. Each has its
own particular problems regarding management.
Patients are often in poor general health and may have
appreciable comorbidities or psychosocial problems.
Different members of the multidisciplinary team need
to collaborate to devise the best management plan for
each patient. Guidelines recommend that teams
include at least clinical oncologists, otorhinlaryngolo›
gists, oromaxillofacial surgeons, and plastic surgeons.10
Ideally, a radiologist and a pathologist with specialist
interests should be included. The contributions of
clinical nurse specialists, speech and language thera›
pists, dieticians, and prosthetics technicians are
indispensable to optimal outcome.
Management
Management of squamous cell head and neck tumours
has to be considered in respect to both the primary site
and potential cervical lymph node metastases. Radio›
therapy and surgery offer equally good long term
results in small early head and neck cancers (fig 1). The
particular subsite of the disease and the likely long
term morbidity usually determine the decision on
management. Generally, function is better after
radiotherapy than after surgery, but treatment time for
surgery is shorter. The performance status and ability
of patients to cope with anaesthetic or to attend daily
for 4›6 weeks of radiotherapy is also taken into
account. Patients themselves may have strong prefer›
ences. Traditionally, more advanced head and neck
cancer is best managed surgically, providing the
tumour is resectable, with postoperative radiotherapy
for poor prognostic situations (box 2).
With large tumours, the defect from excision is
often considerable. The ability to close large defects of
the head and neck has improved greatly over the past
Box 1: Head and neck cancer: guidelines for
urgent referral
• Hoarseness persisting for > 6 weeks
• Ulceration of oral mucosa persisting for > 3 weeks
• Oral swellings persisting for > 3 weeks
• All red or red and white patches on the oral mucosa
• Dysphagia persisting for > 3 weeks
• Unilateral nasal obstruction, particularly when
associated with purulent discharge
• Unexplained tooth mobility not associated with
periodontal disease
• Unresolved neck masses for > 3 weeks
• Cranial neuropathies
• Orbital masses
Box 2: Indications for postoperative
radiotherapy
• Close or involved margins of excision
• Extranodal spread of tumour
• Multiple nodes
• Poorly differentiated pathology with perineural or
perivascular spread
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25 years, with the introduction of pedicled myocutane›
ous flaps and more recently free flaps. Cosmetic disfig›
urement and the time a patient spends in hospital has
lessened considerably. Unfortunately, the increased
capacity for reconstruction has not been accompanied
by an increase in survival, and some substantial recon›
structions are not entirely functionally satisfactory.
Large tumours that were previously unresectable
because of their location, such as tumours at the skull
base—for example, nasopharyngeal carcinoma or
tumours in the neck extending into the mediastinum—
can now, with the advent of new surgical approaches,
often be resected. These techniques sometimes require
the input of other surgical disciplines such as
neurosurgery and cardiothoracic surgery.
Inoperable disease may be treated with combina›
tions of chemotherapy and radiotherapy, but outcomes
generally remain poor, and in some cases of advanced
disease only patients’ symptoms can be treated.
Management of the neck
Surgery is the mainstay of treatment for cervical lymph
node metastases, which are grouped into five levels
(fig 2). With clinical evidence of nodal disease it is clear
that the neck requires treatment, traditionally in the
form of a neck dissection. Surgery has moved away
from radical neck dissections towards modified and
selective neck dissections (see box A on bmj.com). This
preserves function, especially in relation to the
accessory nerve, which if sacrificed usually gives rise to
a stiff and painful shoulder. If clinical evidence of the
presence of enlarged cervical nodes is lacking, but the
expected incidence of node metastases is greater than
20%, it is common practice to treat the neck (see table
A on bmj.com). The incidence of involved cervical
lymph nodes for different sites and stages of tumour is
known from retrospective studies.w2 Watching and
waiting, to see if a node appears, is also practised, and
no prospective randomised trials compare the two
approaches. Prophylactic treatment of the neck may
reduce the rate of systemic metastatic disease.11
Strategies to improve outcomes
Laser treatment
Using lasers, especially in early laryngeal disease, yields
long term survival results equivalent to radiotherapy.12
Although most patients with early laryngeal cancer are
treated with radiotherapy in the United Kingdom,
lasers are used increasingly, as the patients may often
be treated as a day case, and radiotherapy can be held
in reserve for metachronous tumours or recurrence.
The laser is used increasingly for larger lesions and dif›
ferent sites in the head and neck, with encouraging
results relating to survival and function, although there
is little data on voice quality.13
Organ preservation in operable disease
In two large studies, chemotherapy and then
radiotherapy for responding patients or surgery for
non›responding patients gaves equal results for
locoregional control compared with immediate
surgery and then radiotherapy. Survival rates did not
differ between the two groups, but this approach
allowed a number of patients to retain their larynx.14 15
These results have led to a trend towards
preserving organs by giving chemotherapy during
radiotherapy in advanced disease. Mostly, these
strategies have scheduled chemoradiotherapy to the
primary and neck, followed by a neck dissection six
weeks later provided there is a complete response of
the primary tumour.16 An alternative for an inoperable
primary tumour or potentially functionally debilitating
surgery is neck surgery followed by chemoirradiation
to the primary. A prime example of this is in advanced
tongue base tumours, where surgical management
would involve a total glossolaryngectomy.
Addition of chemotherapy to locoregional
treatment
A meta›analysis showed that chemotherapy adminis›
tered during radiotherapy (concurrent chemotherapy)
Fig 1 Patients undergoing head and neck irradiation are immobilised
in a beam direction shell which has been vacuum formed over a
plaster mould of the patient’s head and neck. This allows for
accuracy and reproducibility of the treatment set up, and where
possible irradiation to normal tissues is kept to a minimum by a
system of multileaf collimators (lead shields)
I
II
III
IV V
Fig 2 Nodal groups
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gave an absolute benefit at five years of 8%.17 A number
of randomised controlled trials have been published
since, including the United Kingdom head and neck
study of 971 patients.18 Several of these trials have con›
sistently shown an overall survival benefit to concomi›
tant chemoirradiation compared with radiotherapy
alone, and a systematic review of this group showed an
overall reduction in mortality of 11%.19
These gains in survival come at the expense of
increased acute morbidity and might be equally
produced by an increase in the radiation dose and
potentially therefore not a true improvement in thera›
peutic index.20 Interest focuses on the future use of
radiation protectants such as amifostine and growth
factors (rhGM›CSF).21
The optimum chemotherapy regimen is not yet
known. Platinum combinations, in particular cisplatin
and fluorouracil, are generally regarded as the “gold
standard,” but low dose chemotherapy may be equally
effective as full dose,22 and radiation sensitisers such as
nimorazole have shown similar results.23
Altered radiation fractionation schedules
Conventional radiotherapy consists of one daily
treatment (fraction) Monday to Friday for three to
seven weeks, varying between centres in the United
Kingdom. Total doses vary from 50 Gy to 70 Gy. In the
United States and Europe 60 Gy to 70 Gy are standard.
These schedules are assumed to have the same overall
radiobiological effect, which depends on the relation
between overall time, total dose, and the number of
fractions. They developed through clinical experience
and training, however, randomised controlled trials
have never been used to compare these different “con›
ventional” fractionation schedules.
In the 1980s focus centred on time›fractionation
schedules; low doses per fraction could give reduced
late morbidity.24 This led to trials of hyperfractionation
in which the dose per fraction was small—that is,
divided up into two or three treatments per day instead
of one. With increasing overall treatment time the total
dose had to be increased to achieve the same effect.
Accelerated regimens with shortened overall duration
were therefore investigated, with the aim of reducing
the time in which tumour cell repopulation could
occur. These regimens have been studied by groups at
Mount Vernon, United Kingdom, the Danish head and
neck cancer group, radiation therapy, and oncology
group in the United States, the European Organization
for Research and Treatment of Cancer, and others with
improvements in disease specific survival and loco›
regional control (see box B on bmj.com).
Brachytherapy
Brachytherapy is the implantation of radioactive sources
in soft tissues or body cavities. Some are removed after a
specified number of days—for example, iridium wires or
hairpins; others, where the half life of the isotope is
short, are left in place—for example, gold or iodine seeds
(see fig A on bmj.com). This technique delivers high
doses of radiation to the tumour while sparing healthy
surrounding tissues. Brachytherapy has a number of
useful applications (box 3).
Low dose rate radiotherapy has the disadvantage of
exposing staff to radiation. Patients are nursed in
special lead protected rooms and visiting time is
limited while implants are in place. High dose rate
remote afterloading brachytherapy, which involves
considerable reduction in overall treatment times for
the patient and provides protection for staff, is increas›
ingly being used. No controlled trial has compared its
efficacy with low dose brachytherapy.
Intensity modulated radiotherapy
Intensity modulated radiotherapy is a developing new
technology which can produce an even distribution of
radiation dose within a target volume which follows the
contours of an irregularly shaped tumour. It spares
normal tissues close to or even within a concavity of a
tumour and gives scope for escalation of radiation
dose.25
Quality of life
Quality of life issues in head and neck cancer are cru›
cial given the nature of the disease and its treatment,
which can affect function in vital areas such as speech,
swallowing, breathing, and facial appearance. This may
have enormous sociopsychological impact and cause
physical disability. Despite the importance of quality of
life issues in comparisons of treatments, few clinical
trials report meaningful quality of life data for long
term outcome.
A patient’s perspective
It started with difficulty clearing my throat, then my voice began to fade.
After several appointments with my general practitioner I was sent to an
ear, nose, and throat specialist. He put a camera up my nose and said,
“There is something nasty down there.” I was sent away, recalled for a
biopsy, and sent away again. Eventually I was summoned back to the
department, where a doctor with detached bedside manner announced, “It
is cancer,” and then asked me to wait outside while arrangements were
made for treatment. This abrupt statement was the first indication of just
how serious my condition was, and as I sat alone in that corridor my spirits
were low and my thoughts were black.
I received a course of radiotherapy, attending every day for treatment.
The treatment was successful and my voice returned: I was a happy man.
Sadly, seven months later my voice faded again, and I had trouble breathing.
A visit to the oncology unit resulted in me being admitted to hospital, where
the consultant brusquely announced that he would perform a tracheotomy
to relieve my breathing immediately, and a larger operation to remove my
voice box was also necessary. This would have to wait, however, as the
consultant was abroad on holiday over Christmas and the New Year. I
would lose my voice forever in the year 2000; just the news you need to
hear at Christmas time.
I woke up after surgery on 10 January 2000 and gradually the awful
realisation that my voice, which I had had for 66 years and which my wife
and children knew so well, had gone and nothing was left. I have never fully
discovered exactly what was wrong with my larynx. I know it was cancerous,
but where and why? Was the disease caused by smoking? I hadn’t smoked in
almost 30 years.
I have no doubt that my surgeon was good at his job, but in the days after
my operation it seemed his only concern was how the flesh wounds were
healing. Anything else (like feelings) was obviously someone else’s job.
As healing progressed, I began speech therapy and was assured, “You will
speak again.” Sure enough, after a short difficult period of learning
techniques, I was delighted to be able to greet the gaggle at doctors’ rounds
with, “Good morning everyone.”
Progress has been good, and as my general wellbeing improved I was
introduced to several new speaking techniques and I can now use a new
hands›free system which allows me to speak apparently normally without
using fingers or buttons.
I am always pleased when asked to speak with other patients who are
waiting for the same operation. I try and give them some insight into what
lies ahead and some hope that life in the future can be pretty good again.
Edward Martin, Edinburgh
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A recent large longitudinal study of 357 patients
from Norway and Sweden found that patients with
hypopharyngeal cancer had the worst health related
quality of life score, compared with tumours at other
sites within the head and neck, and that stage had the
strongest impact. Women scored worse in emotional
functioning and older patients scored better for
emotional and social functioning but worse for
physical functioning. At 12 months, quality of life
tended to recover except for senses, dry mouth, and
sexuality.26 27
Palliation
Although a tracheostomy or peg tube can restore vital
functions, a patient with slowly advancing incurable
head and neck cancer can present enormous
challenges. The palliative care team and Macmillan
services have a pivotal role in controlling the
symptoms of advanced head and neck malignancy. Pal›
liative radiotherapy should be used judiciously to avoid
a painful radiation mucositis causing further distress
with little therapeutic gain. Epistaxis, stomal recur›
rence, or proptosis might be controlled with a short
course of radiotherapy, and electron therapy or
brachytherapy can be helpful for recurrence of
tumours in the neck.
Untreated head and neck cancer is often chemo›
sensitive, but response rates tend to be lower in recur›
rent disease. Cisplatin and infusional 5›fluorouracil in
combination is the standard to which new combina›
tions are compared. Docetaxel in combination with
cisplatin shows response rates of around 40%, but so
far does not seem to offer any survival advantage and
its toxicity can be considerable.28 Oral agents such as
fluoropyrimidines—for example, capecitabine—are
under investigation.
Prognosis
Prognosis depends largely on the stage of presenta›
tion, with the single most important factor being the
presence of neck node metastases, which reduces long
term survival by 50%. Overall survival is considerably
different from disease specific survival. These patients
have serious cardiovascular and pulmonary comorbid›
ity because of their drinking and smoking habits and
have a high incidence of death from causes unrelated
to their head and neck cancer.
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Commentary: Head and neck carcinomas in the developing world
William I Wei
The prognosis of patients with squamous cell
carcinoma of the head and neck has improved in West›
ern countries because of better understanding of
disease and advances in treatment. But management in
many developing countries remains suboptimal,
largely because of economic constraints and lower lev›
els of education, which result in a large proportion of
patients presenting late with advanced disease.
In Asia, the incidence of primary carcinoma of the
mouth is high because of factors such as poor oral
hygiene, chewing betel nuts, smoking, and drinking
alcohol.1 Viral infection and dietary and, more impor›
tantly, genetic factors are probably responsible for the
high incidence of nasopharyngeal carcinoma in south›
ern China. Because of this high incidence the
possibility of screening has been discussed at length;
population screening is not cost effective, but it is
important to screen high risk individuals—for example,
the immediate relatives of index cases.2 Education of
the public and primary care doctors is also important
to prevent disease and encourage early presentation.3
The application of new diagnostic tools such as
serological tests and fluorescent light should contrib›
ute towards early diagnosis of both intraoral malig›
nancies and nasopharyngeal carcinomas.4 Although
development of new tools will require more invest›
ment, it is likely to be cost effective because appropriate
effective treatment can be promptly given.
In developing countries, the wide variation in
population size, economic status, ethnic origin, and
belief in traditional medicine is inevitably associated
with varied outcome. A recent review of the
managment of early carcinoma of the larynx in Asia
underlined that the waiting time for treatment, mode
of treatment used, and outcome varied considerably.3
Economic factors are particularly important here. As
Sanderson and Ironside emphasise, new techniques of
reconstruction, improved radiotherapy fractionation
schedules, and the concomitant use of chemotherapy
are now standard treatment in Western countries. In
developing countries, however, surgical expertise is
lacking outside of specialised units in cities. The
relative lack of linear accelerators limits fractionation
schedules, and the cost of chemotherapy limits its use.
Although multidisciplinary management is best, it is
hard to implement such care for patients who live in
rural regions. For these patients, radical treatment is
often used to reduce the chance of recurrence; this may
have to be at the price of some loss of function. Other
factors which doctors have to take into consideration
include patients’ acceptance of treatment and their
ability to comply with close monitoring.
1 Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of
mouth cancer: a review of global incidence. Oral Dis 2000;6:65›74.
2 Wunsch›Filho V, de Camargo EA The burden of mouth cancer in Latin
America and the Caribbean: epidemiologic issues. Semin Oncol
2001;28:158›68.
3 Wei WI. Management of early carcinoma of the larynx: the Asian
perspective. ENT News 2000;9:18›9.
4 Qu JY, Yuen PW, Huang Z, Kwong D, Sham J, Lee SL, et al. Preliminary
study of in vivo autofluorescence of nasopharyngeal carcinoma and nor›
mal tissue. Lasers Surg Med 2000;26:432›40.
Fig 3 Oral cancers are common in Asia. One cause is chewing betel
nuts, with the site of the cancer related to the site at which the nut
is chewed
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